Evidence map›Paper›PMID 26553692›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015

Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali.

Panchali Roy Chowdhury, Christian Meier, Hewad Laraway, Yuxiao Tang, Abraham Hodgson, Samba O Sow, Godwin C Enwere, Brian D Plikaytis, Prasad S Kulkarni, Marie-Pierre Preziosi and 1 more

Open access · bronzeAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 6 countries.

Panchali Roy ChowdhuryCentre for Biological Threats and Special Pathogens, Robert Koch Institut, Berlin, Germany.
Christian MeierCentre for Biological Threats and Special Pathogens, Robert Koch Institut, Berlin, Germany.
Hewad LarawayCentre for Biological Threats and Special Pathogens, Robert Koch Institut, Berlin, Germany.
Yuxiao TangMeningitis Vaccine Project, PATH, Seattle, Washington.
Abraham HodgsonNavrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana.
Samba O SowCentre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali.
Godwin C EnwereMeningitis Vaccine Project, PATH, Ferney-Voltaire, France.
Brian D PlikaytisCenters for Disease Control and Prevention, Atlanta, Georgia.
Prasad S KulkarniSerum Institute of India Limited, Pune.
Marie-Pierre PreziosiMeningitis Vaccine Project, PATH, Ferney-Voltaire, France Meningitis Vaccine Project, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Matthias NiedrigCentre for Biological Threats and Special Pathogens, Robert Koch Institut, Berlin, Germany.
Robert Koch Institute · DECenters for Disease Control and Prevention · USCentre Pour le Développement des Vaccins-Mali · MLNavrongo Health Research Centre · GHSerum Institute of India (India) · INWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundYellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to be introduced in the EPI of countries in the African meningitis belt, and this study reports on the immunogenicity of the YF-17D vaccines in infants when administered concomitantly with measles vaccine and PsA-TT.

methodsTwo clinical studies were conducted in Ghana and in Mali among infants who received PsA-TT concomitantly with measles and YF vaccines at 9 months of age. YF neutralizing antibody titers were measured using a microneutralization assay.

resultsIn both studies, the PsA-TT did not adversely affect the immune response to the concomitantly administered YF vaccine at the age of 9 months. The magnitude of the immune response was different between the 2 studies, with higher seroconversion and seroprotection rates found in Mali vs Ghana.

conclusionsImmunogenicity to YF vaccine is unaffected when coadministered with PsA-TT at 9 months of age. Further studies are warranted to better understand the determinants of the immune response to YF vaccine in infancy. CLINICAL TRIALS REGISTRATION: ISRCTN82484612 (PsA-TT-004); PACTR201110000328305 (PsA-TT-007).

Indexed as

Immunization ScheduleAntibodies, NeutralizingAntibodies, ViralFemaleGhanaHealthy VolunteersHumansInfantMaleMaliMeasles VaccineMeningococcal VaccinesNeutralization TestsYellow Fever VaccineAntibodies, NeutralizingAntibodies, ViralMeasles VaccineMenAfriVacMeningococcal VaccinesYellow Fever VaccineAfricacoadministrationgroup A meningococcal conjugate vaccinemicroneutralization assayyellow fever vaccine

Identifiers

PMID26553692
PMCPMC4639505
OpenAlexW2180144258

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.